Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 2/20 | 0.68 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.68 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.68 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.68 |
| ▸ | F2 | P00734 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 3/20 | 0.66 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.63 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | IDE | P14735 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890035 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 | |
| SCHEMBL18117435 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 | |
| SCHEMBL12551869 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 | |
| SCHEMBL21531161 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 | |
| SCHEMBL25375533 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 | |
| SCHEMBL24974563 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 | |
| SCHEMBL24670280 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 | |
| SCHEMBL24163378 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 | |
| SCHEMBL21151130 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 | |
| SCHEMBL13021124 | 1.00 | PRSS1 (0.68) | PRSS1PRSS2PRSS3TPSAB1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117783543-A | Biotin coupling structure of estradiol and its synthesis method and application | 苏州派博思生物技术有限公司 | 2024-03-29 | — | — | CN | claimed |
| EP-4660629-A1 | METHOD FOR DETECTING TRANSTHYRETIN TETRAMER, AND METHOD FOR EVALUATING STABILITY | SYSMEX CORPORATION (JP) | 2025-12-10 | — | — | EP | disclosed |
| US-20250369975-A1 | METHOD FOR DETECTING TRANSTHYRETIN TETRAMER, AND METHOD FOR EVALUATING STABILITY | SYSMEX CORPORATION (JP) | 2025-12-04 | — | — | US | disclosed |
| EP-3430015-B1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2025-08-06 | — | — | EP | disclosed |
| EP-4269400-B1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE SA (PL) | 2025-07-09 | — | — | EP | disclosed |
| US-12325701-B2 | YKL-40 inhibitors and their therapeutic | MOLECURE S.A. (PL) | 2025-06-10 | — | — | US | disclosed |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | ORYZON GENOMICS S.A. (ES) | 2025-01-14 | — | — | US | disclosed |
| CN-117986608-A | Method for grafting polymer on surface of universal substrate | 烟台先进材料与绿色制造山东省实验室 | 2024-05-07 | — | — | CN | disclosed |
| CN-117783543-A | Biotin coupling structure of estradiol and its synthesis method and application | 苏州派博思生物技术有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-11-02 | — | — | US | disclosed |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-11-02 | — | — | US | disclosed |
| EP-4269400-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | Molecure SA (PL) | 2023-11-01 | — | — | EP | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2022-12-08 | — | — | US | disclosed |
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-12-09 | — | — | US | disclosed |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-11-07 | — | — | US | disclosed |
| EP-3510404-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | Pharmakea, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2018048928-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | KDM1B, KDM1A, KDM7A | PRSS1 2408/4885PRSS2 4139/4885PRSS3 4498/4885 |
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | PRSS1 1431/4885PRSS2 2036/4885PRSS3 1477/4885 |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | PRSS1 219/4885PRSS2 688/4885PRSS3 397/4885 |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | PRSS1 201/4885PRSS2 1139/4885PRSS3 818/4885 |
| US-12325701-B2 | YKL-40 inhibitors and their therapeutic | CHI3L1, CHI3L2, CHIA | PRSS1 222/4885PRSS2 682/4885PRSS3 407/4885 |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | KDM1B, KDM1A, KDM7A | PRSS1 2408/4885PRSS2 4139/4885PRSS3 4498/4885 |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | PRSS1 1647/4885PRSS2 2229/4885PRSS3 1606/4885 |
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | LOXL2, LOXL1, LOXL3 | PRSS1 1316/4885PRSS2 781/4885PRSS3 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.